drugset / Trial / NCT06308913
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
Phase 0
Active not recruiting
10 enrolled
University of Wisconsin, Madison
National Cancer Institute (NCI) · collabNational Institute of Dental and Craniofacial Research (NIDCR) · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is evaluating INCB081776 when given in combination with the checkpoint inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or recurrent metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). 12 participants will be enrolled and can expect to be on study for up to 12 months.
Timeline
- Start
- 2024-09-18
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB081776 | Unknown | 120 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |